Deals

Alcon Turnaround Has Novartis Exploring Spin-off

By Rich Kirkner | January 26, 2017

In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the…

Read More

OIS Index Underperforms Benchmarks in First Quarter Since Inception

By Michael Lachman | January 5, 2017

In October, OIS partnered with EyeQ Research to launch the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our…

Read More
part-two-three-novel-partnerships-11-30-16

Three Novel Partnerships in Ophthalmology (Part Two)

By Michael Smolinsky | November 30, 2016

Two weeks ago, we began reviewing collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical technology, such as…

Read More
As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

By Larry Haimovitch | November 22, 2016

So when does a rumor cease being a rumor and become a reality? It remains to be seen whether all the recent and persistent rumors…

Read More
OIS Index Follows Biotech Stocks Lower in October - OIS Index - Healthegy

OIS INDEX: Trump Bump

By Michael Lachman | November 16, 2016

The OIS Index closed at 962.42 on Tuesday, a week after Donald Trump’s election. Here’s how the collection of 29 publicly traded ophthalmology companies fared…

Read More
Three Novel Partnerships in Ophthalmology - Eye On Innovation Article - OIS - Healthegy

Three Novel Partnerships in Ophthalmology

By Michael Smolinsky | November 8, 2016

The past year has witnessed the formation of several collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical…

Read More
Corneal Inlays Garnering Attention – and Investment - Eye On Innovation Article - Healthegy

Corneal Inlays Garnering Attention – & Investment

By Larry Haimovitch | November 1, 2016

Recent positive reports about two FDA-approved corneal inlays may yet give this market sector a boost heading into 2017. Irvine, CA-based AcuFocus was the first…

Read More
OIS Index Follows Biotech Stocks Lower in October - OIS Index - Healthegy

OIS Index Follows Biotech Stocks Lower in October

By Michael Lachman | November 1, 2016

At last month’s OIS@AAO, we introduced the OIS Index. To learn more about its origins and intent, listen to this OIS Podcast interview. By Michael…

Read More
Regeneron Looks Ahead to ANG2 Antibody after Anti-PDGFR-β Disappoints - Eye On Innovation Article - OIS - Healthegy

Regeneron Looks Ahead to ANG2 Antibody After Anti-PDGFR-β Disappoints

By Rich Kirkner | October 5, 2016

Now that Regeneron has announced that its rinucumab-Eylea (aflibercept) combination treatment for wet age-related macular degeneration (AMD) failed to meet the primary endpoint of a…

Read More
J&J/AMO Deal Remaking Landscape

J&J/AMO Deal Remaking Landscape

By Tom Salemi | September 21, 2016

The evolution of the ophthalmology sector continued with last week’s news that Johnson & Johnson would pay $4.3 billion to acquire Abbott Medical Optics, the…

Read More
OIS Eye On Innovation Article - How Hot Is MIGS? - Healthegy

How Hot is MIGS?

By Larry Haimovitch | September 8, 2016

The string of approvals and acquisitions in the microinvasive glaucoma surgery space has been one of ophthalmology’s more promising stories. The news shone a bright…

Read More
Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Can Ocular Therapies Diversify Biogen Portfolio?

By Michelle Dalton | June 29, 2016

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.